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Background/objectives: Therapy using bone marrow (BM) cells has been tested experimentally and clinically
due to the potential ability to restore cardiac function by regenerating lost myocytes or increasing the survival
of tissues at risk after myocardial infarction (MI). In this study we aimed to evaluate whether BM-derived
mononuclear cell (MNC) implantation can positively inﬂuence the post-MI structural remodeling, contractility
and Ca(2+)-handling proteins of the remote non-infarcted tissue in rats.
Methods and results: After 48 h of MI induction, saline or BM-MNC were injected. Six weeks later, MI scars
were slightly smaller and thicker, and cardiac dilatation was just partially prevented by cell therapy. However,
the cardiac performance under hemodynamic stress was totally preserved in the BM-MNC treated group
if compared to the untreated group, associated with normal contractility of remote myocardium as analyzed
in vitro. The impaired post-rest potentiation of contractile force, associated with decreased protein expression
of the sarcoplasmic reticulum Ca2+-ATPase and phosphorylated-phospholamban and overexpression of
Na(+)/Ca(2+) exchanger, were prevented by BM-MNC, indicating preservation of the Ca(2+) handling.
Finally, pathological changes on remodeled remote tissue such as myocyte hypertrophy, interstitial ﬁbrosis
and capillary rarefaction were also mitigated by cell therapy.
Conclusions: BM-MNC therapy was able to prevent cardiac structural and molecular remodeling after MI,
avoiding pathological changes on Ca(2+)-handling proteins and preserving contractile behavior of the viable
myocardium, which could be the major contributor to the improvements of global cardiac performance after
cell transplantation despite that scar tissue still exists.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Ischemic heart disease frequently leads to myocardial remodeling
and heart failure with impaired life quality, playing an important
role in cardiovascular deaths. Due to the impact on public health,
experimental therapeutic studies regarding myocardial infarction (MI)
and heart failure are often focused. In thisway,myocardial implantation
of stem cells, such as those derived from the bone marrow (BM), has
been tested in both experimental and clinical studies for more than a
decade [1,2].by grants-in-aid fromConselho
Pq) and Fundação de Amparo à
iológicas, CCS/UFES, AvMarechal
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antos).
e reliability and freedom from
ation.
Ltd. All rights reserved.The main mechanism originally proposed for BM-derived cell
therapy involved the potential capability to fuse with or differentiate
into contractile myocytes and the ability to form new vessels, since
adult BM contains pluripotent cell populations [3]. Currently, it has
been accepted that tissue regeneration or differentiation plays a
minor role, ascribing a major importance to the paracrine-mediated
effects on the infarct and border zone by BM-derived stem cells [4].
The functional beneﬁts identiﬁed after cell therapy are related to
improvement of global cardiac function as assessed by in vivo and in
vitro approaches [5–12]. Angiogenesis [8,9,13–15] and reduction of
apoptosis [14,16,17] and ﬁbrosis [9,10,12,17] essentially in infarcted
and adjacent areas have been reported. Nevertheless, rare information
has been provided about remodeling and function of reminiscent and
remote regions of the failing left ventricle (LV) after BM-derived cell
therapy [7]. In post-MI physiopathology studies, multicellular in vitro
preparations of the non-infarcted myocardium allow to evaluate the
contractility without inﬂuences of the LV ﬁbrotic scar or cavity dimen-
sions, resembling the actual in situ mechanics. In the present study, we
3830 L. dos Santos et al. / International Journal of Cardiology 168 (2013) 3829–3836demonstrated that intramyocardial injection of BM-derivedmononucle-
ar cells (MNC) in rats reduced infarct size and attenuated structural and
functional remodeling of the myocardium remote to the infarct and
implantation site, which contributed to the improvement of cardiac
performance. In addition, for the ﬁrst time using BM-MNC in a rodent
model of MI, we showed that this approachwas associated with preser-
vation of the mechanics of spared myocardium by attenuating deleteri-
ous changes on the calcium handling.
2. Material and methods
2.1. Used animals and MI model
Male and female 10–12 week old Lewis inbred rats were used. Animals received
humane care and all procedureswere in compliancewith protocols approved by the Insti-
tutional Research Ethics Committee of the Federal University of São Paulo (No. 1468.05).
The authors of this manuscript have certiﬁed that they comply with the Principles of
Ethical Publishing in the International Journal of Cardiology. MI was induced by
ligation of the anterior descending coronary artery in 30 female rats as previously
described [15,18]. Under anesthesia with ketamine (50 mg/kg) and xylazine
(10 mg/kg) intraperitoneally, orotracheal intubation and mechanical ventilation
were performed (rodent ventilator, Harvard Apparatus Mod 683; Holliston MA,
USA), and through a left thoracotomy the coronary artery was tied with a 6-0
polypropylene suture. The same surgical procedures were performed without
coronary occlusion in another 8 rats, named as Sham-operated (Sham) group.
2.2. Isolation and implantation of BM-derived MNC
BM was harvested from male Lewis inbred rats and BM-MNC were isolated as
previously reported [15,19]. After the rats were sacriﬁced, femurs and tibias were
excised and placed in phosphate-buffered saline with penicillin G (100 U/ml) and
streptomycin (100 μg/ml), and the BM was ﬂushed out of the bones with Dulbecco's
modiﬁed Eagle's medium. The BM-MNC were isolated by centrifugation through a
density-gradient (3:10 Ficoll-Paque Plus; Amersham Biosciences, Uppsala, Sweden)
and then suspended in sterile saline. Trypan blue dye (0.4%; Sigma, St. Louis, MO,
USA) was used to conﬁrm cell viability, and only samples with viability N90% were
used. Forty-eight hours after coronary occlusion, a suspension of 6 × 106 BM-MNC in
100 μl sterile saline (BM-MNC group), or 100 μl of cell-free saline solution (Saline
group) was injected into the myocardium at 3 points along the infarct border zone
using a 30-gauge needle. The cell and saline injections were performed under direct
observation of the LV free wall in open chests to ensure that there was no leakage of
solution. Outcome parameters were assessed 6 weeks after coronary occlusion and
cell implantation. To evaluate whether injections could deliver BM-MNC in the host
ventricle, the Y chromosomes from male donor BM-MNC were searched in the LV
sampled from female rats with MI, sacriﬁced immediately after cell implantation,
by using a polymerase chain reaction (PCR). Additionally, implanted cells were also
searched in samples collected 6 weeks after surgery. Genomic DNA was extracted
and a conventional PCR was performed using primers designed based on a partial
sequence of the rat Sry gene, which amplify the male sex-determining region on the
Y chromosome (forward: 5′-AGT GTT CAG CCC TAC AGC CTG AGG AC-3′ and reverse:
5′-GCT GCA ATG GGA CAA CAA CCT ACA CAC-3′) [15].
2.3. Echocardiography
Infarct size estimation and LV function were evaluated by echocardiography six
weeks after MI and BM-MNC therapy. Examination was done by one observer blinded
to the animal group, with a HP SONOS 5500 (Philips Medical Systems, Andover, MA,
USA) and a 12-MHz/2-cm transducer, according to Santos et al. [18]. The LV end-
diastolic and end-systolic transverse areas were measured and fractional area shorten-
ing (FAS) was calculated. The parameters of mitral diastolic inﬂow velocity curves
derived from pulsed-wave Doppler (peaks of E- and A-wave velocities) were used to
assess diastolic function. The relative infarct extension was measured by echocardiog-
raphy at basal, middle and apical levels; the length of arc corresponding to the akinetic
portion (infarct scar) and the total perimeter of the LV endocardial border were
analyzed at the end of diastole; and the relative MI size was expressed as % of the LV
transverse perimeter occupied by the infarct averaged in the three planes. Recently,
we have shown that this echocardiographic approach provides credible estimates of
infarct size that are comparable to histochemical methods [20].
2.4. Direct hemodynamic evaluation
Thereafter, an invasive hemodynamic evaluation was performed using a micro-
manometer (MikroTip™ 2F; Millar Instruments Inc., Houston, TX, USA) that was
inserted into the LV cavity through the carotid artery to measure the intraventricular
pressure. Through a brief right thoracotomy, a ﬂow ultrasound probe (Transonic
Systems Inc., Ithaca, NY, USA) was positioned around the ascending aorta to estimate
LV ejection. Protocols were performed in closed chest anesthetized animals and the
following parameters were analyzed: LV systolic and end-diastolic pressures, rate ofchange of LV pressure, heart rate, cardiac output, stroke volume and strokework. Stroke
work was calculated as the product of stroke volume × (systolic pressure − end-
diastolic LV pressure). After evaluation under basal conditions, cardiac performance
was tested by acquiring the hemodynamic parameters under a sudden afterload stress,
promoted by pressure-overload using a single vasoconstrictive phenylephrine injection
(PHE, l-phenylephrine hydrochloride, Sigma, St. Louis, MO, USA). PHE doses were
individually adjusted (15–25 μg/kg, intravenously) to produce comparable blood
pressure increases of 50–70% over the baseline [21].
2.5. In vitro myocardial contractility
Preparations of isolated LV papillary muscles under isometric contractions were
performed as previously described [22]. The heart was quickly removed and the poste-
rior papillary muscle of LV was carefully dissected and vertically mounted in an organ
bath heated at 29 °C and 100% oxygenated. Muscle was attached to a force transducer
(GRASS FT-03, Astro-Med, Inc., RI, USA) connected to a micrometer for adjustment of
muscle length. The composition of the Krebs–Henseleit solution was as follows: (in
mM) 135 NaCl; 4.69 KCl; 1.5 CaCl; 1.16 MgSO4; 1.18 KH2PO4; 5.50 glucose; 10 U insulin
and HEPES 20 buffered at pH 7.3 to 7.4. The preparation was stimulated by platinum
electrodes at a frequency of 0.2 Hz, using square-wave pulses of 5-ms duration, and
voltage adjusted to a value 10% greater than minimum required producing mechanical
response. After 60 min of stabilization at low loading conditions, muscle was loaded to
contract isometrically and stretched to peak length of its length–tension curve (Lmax).
Tests were performed at Lmax (optimum length for contraction), isometric tension was
evaluated by force normalized to the muscle cross-sectional area (g·mm−2) and the
following parameters were obtained: resting tension (RT), peak of developed tension
(DT) and its ﬁrst time derivative (dT/dt), time to peak tension (TPT), time to 50% of
relaxation (TR50). Experimental protocol was composed of an analysis of the papillary
behavior in: 1) length–tension curves (by stretching muscles from 92 to 100% of Lmax);
2) relative post-rest contractions (using 6, 10, 15, 30, 45 and 60 s of pause
duration); 3) contractile response to calcium (increasing Ca2+ concentration from
1.5 to 2.5 mM in bath solution); and 4) contractile response to β-adrenoceptor agonist
(adding isoproterenol 5 μM in bath solution).
2.6. Western blotting
Protein expression of sarcoplasmic reticulum Ca2+-ATPase (SERCA2), phospholamban
(PLB), phosphorylated phospholamban (Ser16-PLB),α1 andα2 isoforms of Na+, K+-ATPase
(NKA), and Na+/Ca2+-exchanger (NCX) was analyzed byWestern blotting in myocardium
microsomal fractions according to previously described [23]. Samples were collected from
non-infarcted LV posterior wall and interventricular septum of each experimental group
and compared to equal mass of sample from similar LV regions from the Sham group. To
prepare the microsomal fractions of proteins, tissue homogenates were centrifuged at
10,000 ×g (10 min at 4 °C) followed by an ultra-centrifugation at 100,000 ×g (60 min).
The pellets, representing the microsomal fraction, were resuspended in Tris–EDTA buffer
(in mM: Tris 50, EDTA 1.0, pH = 7.4) and protein concentration was measured by the
Bradford's method. Equal protein samples (25 μg) from the reminiscent LV of each group
and pre-stained molecular SDS-PAGE standards (Bio-Rad, CA, U.S.A.) were electrophoreti-
cally separated on 7.5–12% SDS-PAGEs and then transferred to polyvinyl diﬂuoride
membranes overnight at 4 °C, using a Mini Trans-Blot Transfer Cell system (Bio-Rad, CA,
U.S.A.). Transferring efﬁciency and protein charging equality were veriﬁed by gel Ponceau
S 1% staining (Caledon laboratories, Ontario, Canada) [24]. Then, membranes were blocked
(Tris-buffered solution with 5% powdered non-fat milk) and incubated overnight with the
following primary monoclonal antibodies: anti-SERCA2 (1:2500, Abcam Inc., MA, USA),
anti-PLB (0.25 μg/ml, Upstate Biotechnology, Lake Placid, NY, USA) or anti-phospho-
Ser16-PLB (1:1000, Upstate Biotechnology), anti-α1 Na+/K+-ATPase (1:10,000, Upstate
Biotechnology), anti-α2 Na+/K+-ATPase (1:5000, Upstate Biotechnology) or anti-NCX1
(1:1500, Swant, Switzerland). After washing, the membranes were incubated with a
secondary antibody conjugated to horseradish peroxidase (1:3000, Bio-Rad, CA, USA). The
membranewas thoroughly washed and the immunocomplexeswere detected using an en-
hanced horseradish peroxidase/luminol chemiluminescence system (ECL Plus, Amersham
International plc, Little Chalfont, UK) and then subjected to autoradiography. Protein blots
were quantiﬁed by Scion Image software (Scion based on NIH image) in arbitrary units of
optical density and normalized by average of values measured for control samples (Sham
group) in each membrane.
2.7. Biometry, histology and morphometry
Before the excision of the papillary muscle, the left and right ventricles were
weighed separately, in order to use the ventricle mass divided by the body mass as
an index suggestive of ventricular hypertrophy. After papillary muscle dissection and
LV sample collection for protein assays, the LV samples were anatomically remodeled
and ﬁxed in 10% buffered formalin for 24 h, embedded in parafﬁn, and transversely
cut into 3 μm sections. Sections were mounted onto slides and stained with hematox-
ylin and eosin for myocyte analysis, Picrossirius red for ﬁbrosis evaluation, or periodic
acid-Schiff for capillary density quantiﬁcation. A computerized image acquisition
system (Leica Imaging Systems, Bannockburn, IL, USA) was used for the analyses.
Histological analysis was performed only in the remote non-infarcted myocardium
mainly composed of interventricular septum and posterior wall of the LV. This was
used to evaluate tissue remodeling blinded to the experimental group. As an estimative
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50–70 myocytes cut longitudinally for each animal, and calculated according to
the following equation: nuclear volume = π × D × d2 / 6 where d = shorter nuclear
diameter and D = longer nuclear diameter [25]. Fibrosis in the remote non-infarcted
LV was considered as the collagen ﬁbers not including stained scars and perivascular
ﬁbers. After digitalization, the red-stained areas were quantiﬁed as the average
percentage of the total area from each of 5 randomized 200× magniﬁcation ﬁelds
per animal. Capillary and myocyte densities were evaluated in 6 randomized 400×
magniﬁcation ﬁelds per animal, where the ﬁbers were cut transversally. Capillarity
was expressed as the total amount per area (capillaries/mm2) and as the capillary/
myocyte ratio. In addition, the thickness of the scarred myocardial wall was deter-
mined in the mid-portion of the infarction in 4 transverse LV histological sections.
2.8. Statistical methods
Student's t-test, and one-way ANOVA followed by Tukey's post hoc test were used,
when appropriate, for statistical analysis of the data. Linear regressions with comparison
of its slopes were used to evaluate the papillary length–tension curves. GraphPad Prism
5.0 was used for graphs and statistical analysis. Differences at the P-value b 0.05 were
considered signiﬁcant. Results are expressed as mean ± standard error of the mean
(SEM).
3. Results
3.1. MI outcomes and BM-MNC implantation
Twenty-seven rats survived coronary occlusion 48 h after surgery,
and 22 rats exhibited typical electrocardiographic signs of infarction,
as deﬁned by a Q wave in the D1 lead together with ÂQRS and ÂT
located between 0 and 240 degrees [26]. The infarcted animals were
randomized in Saline (n = 12) or BM-MNC (n = 10) injections.
During the 6-week follow-up, only 1 rat died, from the Saline group.
PCR for Sry produced the expected ~400pb fragment in male
hearts used as positive controls, but not in female hearts used as
negative control. This sequence was also identiﬁed in each sample
collected immediately and 6 weeks after implantation of male-
derived BM-MNC in the female infarcted hearts.
Six weeks after MI production and BM-MNC implantation, the
infarct relative size was smaller when compared to the Saline group
(Table 1). Furthermore, by transversal planes, the LV scar was longerTable 1
Morphologic and functional parameters of experimental groups.
Sham Saline BM-MNC
Biometry
Body weight (g) 221 ± 9 219 ± 7 196 ± 9
LV wt/body wt (mg·g−1) 2.31 ± 0.10 2.97 ± 0.08⁎ 2.62 ± 0.09⁎,
#
RV wt/body wt (mg·g−1) 0.64 ± 0.05 1.26 ± 0.08⁎ 0.82 ± 0.03#
PWC (%) 78.76 ± 0.30 81.83 ± 0.29⁎ 79.31 ± 0.27#
Infarct morphology
Relative size (% LV) – 44.5 ± 1.4 38.3 ± 1.1#
Scar length (mm) – 12.3 ± 0.8 9.2 ± 0.4#
Scar thickness (mm) – 0.63 ± 0.04 0.93 ± 0.04#
Echocardiography
LVDA (mm2) 27.4 ± 1.7 58.9 ± 2.5⁎ 40.8 ± 1.9⁎,
#
FAS (%) 59.1 ± 1.1 32.4 ± 1.7⁎ 42.5 ± 1.2⁎,
#
E/A ratio 2.06 ± 0.11 5.29 ± 0.66⁎ 3.26 ± 0.54#
Hemodynamics
LVSP (mm Hg) 119.1 ± 4.0 107.2 ± 5.5 111.2 ± 4.5
LVEDP (mm Hg) 4.4 ± 0.6 16.3 ± 2.7⁎ 4.9 ± 1.2#
Heart rate (bpm) 358 ± 10 338 ± 13 367 ± 10
+dP/dtmax (mm Hg·s−1) 9635 ± 382 7227 ± 367⁎ 9035 ± 344#
−dP/dtmax (mm Hg·s−1) −5995 ± 248 −5018 ± 275⁎ −5774 ± 344#
Cardiac output (ml/min) 49.7 ± 4.4 39.4 ± 4.6 45.6 ± 4.9
Left ventricle (LV); pulmonary water content (PWC); left ventricular diastolic area
(LVDA); fractional area shortening (FAS); relation between velocity of E and A waves
(E/A ratio); left ventricular systolic (LVSP) and end-diastolic pressures (LVEDP);
maximal rate of pressure rise (+dP/dtmax) and decline (−dP/dtmax). Sham (n = 8);
Saline (n = 11); BM-MNC (n = 10). Values are mean ± SEM.
⁎ P b 0.05 vs. Sham.
# P b 0.05 vs. Saline.and thinner in non-treated versus BM-MNC treated animals, sug-
gesting a reduction of infarct expansion (Table 1).
3.2. Global cardiac function
Echocardiography revealed chamber dilatation associated with
systolic and diastolic dysfunctions in the MI group injected with sa-
line (Table 1). However, therapy with BM-MNC reduced LV dilatation
and improved fraction of LV shortening. Also the elevation of E/A ratio
was mitigated in the cell-treated rats.
By direct hemodynamic evaluation (Table 1), elevated LV end-
diastolic pressure (EDP) and depressed ﬁrst derivative of pressure
(+dP/dtmax) observed after MI were signiﬁcantly prevented by
BM-MNC injection. Under basal conditions we did not identify signiﬁ-
cant changes in cardiac output (CO), stroke volume (SV) or stroke
work (SW) generation in infarcted rats when compared to Sham.
In the Sham group, response to afterload stress included increment
on +dP/dtmax and relative maintenance on EDP and SV, associated
with SW recruitment (Fig. 1). Conversely, MI untreated rats exhibited
elevation on EDP without signiﬁcant +dP/dtmax increase, associated
with marked reduction on SV and SW. As shown in Fig. 1, BM-MNC
therapy signiﬁcantly prevented these pathological changes on cardiac
performance. Noteworthy, the BM-MNC group increased +dP/dtmax
and SW, with attenuated fall in LV ejection under afterload stress.
3.3. In vitro myocardial contractility
Typical papillary mechanical recordings are shown in Fig. 2A and
measurements under steady state are summarized in Table 2. Both
contraction and relaxation parameters, which were impaired inFig 1. Repercussions induced by sudden afterload stress in LV maximal rate of pressure
rise (+dP/dtmax); stroke volume; cardiac work and LV end-diastolic pressure. Positive
or negative values result from relative increase or decrease on that parameter. Sham
(n = 8); Saline (n = 7); BM-MNC (n = 7). Values are means ± SEM. *P b 0.05 vs.
Sham; #P b 0.05 vs. Saline.
Table 2
Papillary muscle mechanics under isometric contraction.
Sham Saline BM-MNC
Developed tension (g·mm−2) 6.07 ± 0.32 2.98 ± 0.26⁎ 5.64 ± 0.41#
Resting tension (g·mm−2) 1.10 ± 0.11 1.39 ± 0.12 1.17 ± 0.10
+dT/dtmax (g·mm−2·s−1) 51.4 ± 2.4 26.5 ± 2.3⁎ 46.5 ± 3.1#
−dT/dtmax (g·mm−2·s−1) −21.8 ± 1.4 −11.6 ± 1.3⁎ −19.9 ± 1.8#
TPT (ms) 169 ± 12 220 ± 9⁎ 189 ± 9
TR50 (ms) 156 ± 8 226 ± 16⁎ 180 ± 10#
Maximum rate of tension development (+dT/dtmax) and decline (−dT/dtmax); time to
peak tension (TPT) and time to 50% relaxation (TR50). Sham (n = 7); Saline (n = 6);
BM-MNC (n = 7). Values are means ± SEM.
⁎ P b 0.05 vs. Sham.
# P b 0.05 vs. Saline.
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BM-MNC group (Table 2). Inotropic responses to increased extracel-
lular calcium or isoproterenol (Fig. 2B and C, respectively) were
signiﬁcantly depressed in the Saline group, but in the BM-MNC treat-
ed group the force gain was equivalent to Sham. In response to
stretching (Fig. 2D), the best ﬁtting of the length–tension relation
(linear regression) resulted in lower slope in Saline (0.12 ±
0.02 g·mm−2/% Lmax) if compared to Sham (0.29 ± 0.01), and appar-
ently normal in the BM-MNC group (0.25 ± 0.02) (Fig. 2E); regarding
the relation between stretching and passive tension, Neperian
logarithm transformations of RT values were needed to better ﬁt on
linear regressions (Fig. 2F). As a result, only slopes from Saline
injected group (0.20 ± 0.02 logn[RT] / % Lmax) were higher than
others (Sham: 0.15 ± 0.01; BM-MNC: 0.14 ± 0.01) suggesting an
increased stiffness. As shown in Fig. 3A, the post-rest contraction
protocol evidenced that the papillary muscles from Sham rats exhibit
potentiation proportional to the pause period. This phenomenon,Fig. 2. In panel A: Original representative recordings of papillary muscles isolated from a Sha
post-MI transplanted with bone marrow cells (BM-MNC). Inotropic response to increased
protocol (D) and summary data of developed tension (E) and passive tension (F) in respon
(n = 6); BM-MNC (n = 7). Values are means ± SEM. *P b 0.05 vs. Sham; #P b 0.05 vs. Salwhich allows to indirectly evaluate sarcoplasmic reticulum function
and calcium handling, was signiﬁcantly depressed in Saline but
preserved in the BM-MNC group (Fig. 3B).m-operated rat (Sham), a post-MI injected with cell-free saline solution (Saline), and a
Ca2+ (B) or isoproterenol (C) on bath solution. Example record of a stretch–tension
se to stretching. Bars represent slopes of the linear regressions. Sham (n = 7); Saline
ine.
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Western blot analysis (Fig. 4) showed that post-MI remodeled
myocardium from the Saline group contained lower levels of
SERCA2, total and phosphorylated PLB when compared to Sham,
supporting an impaired SR Ca2+ uptake function. Furthermore, NCX
was overexpressed in LV from infarcted rats. Nevertheless, these
changes were signiﬁcantly prevented in BM-MNC treated hearts
that exhibited SERCA2, PLB and NCX contents very similar to Sham.
While α1 isoform of NKA remained unchanged in all groups, the
diminished content of α2-NKA in the Saline group was not prevented
by the BM-MNC therapy.3.5. Biometry and morphometry
Cardiac masses are presented in Table 1. Although the body mass
was similar between the groups, the LV and RV masses as a function
of body mass in the Saline group were signiﬁcantly increased when
compared to Sham, while the group receiving BM-MNC had these
parameters preserved. Histological analysis on the remodeled
myocardium remote to the infarct showed a signiﬁcant increase in
the myocyte nuclei volume estimated in Saline injected hearts,
which was partially prevented by BM-MNC (Fig. 5G). As a result, the
myocyte density in the Saline group was lower than Sham and
BM-MNC (Fig. 5H). In addition, cardiac tissues from Saline group
exhibited low capillary densities and capillary/myocyte ratio, while
BM-MNC therapy normalized these parameters (Fig. 5I–J and
representative microphotographs in 5A–C). Interstitial collagen was
increased in the Saline but apparently normal in the BM-MNC group
(Fig. 5K, representative microphotographs are in 5D–F).Fig. 3. In panel A: Example record of post-rest potentiation protocol in papillary muscle
isolated from a Sham-operated rat. Arrow heads indicate the pauses of stimulation. In
B: Effect of increasing pause durations on the relative contraction PRC/SSC (post-
rest divided by steady state contraction). Sham (n = 7); Saline (n = 6); BM-MNC
(n = 7). Values are means ± SEM. *P b 0.05 vs. Sham; #P b 0.05 vs. Saline.4. Discussion
Cell therapies for cardiac repair are mainly aimed to reduce infarct
damage and ﬁnally attenuate the dysfunction associated to pathological
remodeling. In the present study, we conﬁrmed that intramyocardial
injection of BM-MNC in rats, 48 h after coronary occlusion, can reach
this goal, since this therapy reduced infarct size and reduced cardiac
dysfunction and lung congestion. Although the exact mechanisms are
not completely understood, here we credited it to an improvement of
the contractility of remote non-infarcted myocardium after BM-MNC
therapy, restored expression of proteins involved in calcium mobiliza-
tion, preserved capillarity and reduced interstitial ﬁbrosis and myocyte
hypertrophy.
The effectiveness of BM-MNC injections was conﬁrmed by detec-
tion of the Sry gene from male cells in host female samples collected
immediately after implantation. Compared to other routes of injec-
tion, we previously demonstrated that intramyocardial delivery is
more efﬁcient for cell survival and cardiac retention, which potentiat-
ed its beneﬁcial effects in the ischemic myocardium [19]. Although
conventional PCR does not allow estimation of cell engraftment, a
long-term permanence of implanted cells seems to be irrelevant,
since the current literature distrusts a direct regenerative capability
of these BM-derived cells [5,17,27]. Independent of the mechanism,
i.e. regenerative or paracrine, the number of transplanted cells in
the host tissue, at the adequate therapeutic window, such as the
acute phase, is rationally critical for cardiac applications including in
patients [28].
Our echocardiographic and hemodynamic data corroborate previ-
ous ﬁndings of BM-MNC related beneﬁts regarding cardiac dilatation
and dysfunction [5,8,11,13,17,27,29,30]. These positive outcomes
have been credited to the ability of the implanted cells in reducing
ischemia and necrosis, and/or regenerating lost tissue; anyway,
diminishing the infarct extension [5,8,11,13,31]. Nevertheless,
despite the sizeable scars remaining in the infarcted rats receiving
BM-MNC, there was a surprisingly effective response under sudden
afterload hemodynamic stress, comparable to Sham. As a result, this
remarkable effect should not be credited only to reduced MI scar. In
previous works, we have proposed this hemodynamic stress test as
a practical method to evaluate cardiac performance in rats, which pri-
marily depends on: i) LV chamber size; ii) response to myocardial
stretch; and iii) the intrinsic myocardial contractility [19,21]. Since
BM-MNC therapy partially reduced the post-MI ventricular dilatation,
the adequate cardiac performance could be attributed, at least in part,
to this beneﬁt on chamber size. In addition, effects on other compo-
nents of this response were clearly evidenced. While cardiac muscle
isolated from infarcted group exhibited depressed response to
stretching, suggesting that Frank–Starling mechanism was impaired
or exhausted, cell therapy signiﬁcantly preserved it. Moreover,
contractility of the reminiscent myocardium was also preserved by
cell therapy, including inotropic responses to β adrenoceptor stimula-
tion. Because cardiomyocyte dysfunction is recurrently ascribed
to changes on Ca2+-handling [32], we also intend to investigate
whether BM-MNC therapy could preserve the mechanics of remote
non-infarcted myocardium by ameliorating the SR function and mod-
ulating the main Ca2+-handling proteins. The contractile response to
rest of stimulation and to increasing Ca2+, which indirectly evaluates
excitation–contraction coupling [33], was substantially depressed in
the MI group. Supporting this functional data, we observed here a
signiﬁcant reduction on protein content of SERCA2, PLB-Ser16 and
α2-NKA, and an overexpression of NCX. While the impaired SR Ca2+
uptake contributes to defective storing function, the overexpressed
NCX with reduced α2-NKA intensiﬁes the Ca2+ withdrawn through
the membrane [34]. In the BM-MNC group, post-rest potentiations
and Ca2+-handling protein expression on remote non-infarcted
myocardium were substantially normalized, despite of no effects on
α2-NKA isoform, suggesting effects on speciﬁc molecular targets.
Fig. 4. Protein content of sarcoplasmic reticulum Ca2+-ATPase (SERCA2), phospholamban (PLB), phosphorylated phospholamban (Ser16-PLB), α1 and α2 isoforms of Na+,
K+-ATPase (NKA), and Na+/Ca2+-exchanger (NCX) on microsomal fractions of reminiscent myocardium from experimental groups. Sham (n = 6); Saline (n = 6); BM-MNC
(n = 6). Bars are means ± SEM, and lower pictures are example Western blots. *P b 0.05 vs. Sham; #P b 0.05 vs. Saline.
3834 L. dos Santos et al. / International Journal of Cardiology 168 (2013) 3829–3836Moreno-Gonzales et al. described that cell therapy can enhance Ca2+
sensitivity of the remote myocardium without effects on myosin and
troponin isoforms [6] indicating a modulation on the Ca2+-handling.
In addition, Lee et al., by using BM-MNC or skeletal myoblasts, identi-
ﬁed that the impaired Ca2+ transient and the SR Ca2+ leak observed
in failing cardiomyocytes were normalized after therapy, although
varying with the type of cell used [7]. Taking together, because the
BM-MNC therapy mitigated the contractile dysfunction and pre-
served the Frank–Starling mechanism of the remnant cardiac muscle,
the improved LV performance is reasonable and physiologically
supported.
Similar towhat was observed in our results, the post-MI remodeling
is constantly evidenced in the reminiscent LV tissue [35,36]. Regarding
the BM-MNC effects, the biometrical and histological indications of
myocardial hypertrophy were partially prevented in rats receiving
BM-MNC, as well as changes on capillarity and collagen deposition on
the remote tissue.
Injection of BM-derived cells can indeed lead to less ﬁbrosis in both
the border zones and adjacent areas [10,11] probably due to paracrinemodulation of cardiac ﬁbroblasts [12,37]. According to what was
presented here, also in the myocardium remote to infarct/healing re-
gions BM-MNC therapy signiﬁcantly mitigated interstitial ﬁbrosis,
being the structural substrate by which the cell therapy restrained the
diastolic dysfunction and preserved the passive mechanical properties
of the surviving muscle. In addition, vascular neoformation has been
the most studied effect involving stem cell therapy for MI, being a
consensus that BM-MNC plays a paracrine-mediated action on the bor-
der zone microvasculature rather than differentiates in vascular cells
[5,13,14,31]. Once again, few authors have studied the myocardium
remote to implant [31]. Here we have presented positive long-term
effects of BM-MNCon themicrovasculature in a sitewhere the presence
of injected cells is unlikely, which reinforces an indirect effect. This
preservation of capillarity on reminiscent myocardium could support
tissue perfusion and prevent ischemic episodes, arrhythmias, and
ﬁnally contractile dysfunction.
Actually, we previously reported that the primary beneﬁt from
implanted BM-MNC may be improving border zone healthy and
reducing infarct expansion, therefore preventing wall thinning and
Fig. 5. Representative microphotographs of the remote remodeled myocardium stained with (A–C) Periodic acid-Schiff for capillary counting (400× original magniﬁcation, arrows
indicate some capillaries), and (D–F) eosin–Picrossirius red for interstitial ﬁbrosis evaluation (200× original magniﬁcation). Remodeling parameters including myocyte hypertro-
phy (G–H), capillarity (I–J), and interstitial ﬁbrosis (K) were evaluated in remote myocardial samples from experimental groups. Bars are means ± SEM. *P b 0.05 vs. Sham;
#P b 0.05 vs. Saline.
3835L. dos Santos et al. / International Journal of Cardiology 168 (2013) 3829–3836scar dyskinesis, and consequently sustaining that effect observed on
systolic function [15]. As also proposed by Moreno-Gonzales et al. [6],
a possible explanation is that injected BM-MNC could play beneﬁcial
paracrine actions on the infarct and border zones by reducing ischemia,
limiting myocyte death and providing neoangiogenesis and, therefore,
reducing global load of the heart and attenuating those structural and
molecular changes related to myocardial remodeling.
In summary, our study indicates that this therapy provides sig-
niﬁcant beneﬁts facing the structural remodeling of that reminiscent
tissue, such as decreasing interstitial ﬁbrosis and normalizing capil-
larity, which could contribute to adequate ventricular compliance
and perfusion. Furthermore, cell transplantation perhaps also
inﬂuence cardiomyocyte remodeling, preserving its contractile re-
sponse by mitigating maladaptive changes on the Ca2+-handling
protein proﬁle. Thus, we have presented evidences that BM-MNC
implantation improves cardiac function, associated with reduced
pathological remodeling of the viable myocardium remote to an
infarct in rats, reinforcing its therapeutic potential for ischemic
cardiac repair.Acknowledgments
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